The post ProShares’ stablecoin-ready ETF posts ‘insane’ $17B trading debut appeared on BitcoinEthereumNews.com. Journalist Posted: February 21, 2026 A money marketThe post ProShares’ stablecoin-ready ETF posts ‘insane’ $17B trading debut appeared on BitcoinEthereumNews.com. Journalist Posted: February 21, 2026 A money market

ProShares’ stablecoin-ready ETF posts ‘insane’ $17B trading debut

A money market fund targeting issuers regulated under the U.S stablecoin law, GENIUS Act, has made a new record for debut trading volume. 

The ProShares GENIUS Money Market ETF (NYSE: IQMM) saw a whopping $17 billion in trading volume.

For context, BlackRock’s iShares Bitcoin ETF (IBIT) saw $1 billion in day-one volume, while its other product, the BlackRock ESG ETF, saw $2 billion. 

This was eight times the previous record, noted Bloomberg ETF analyst Eric Balchunas.

He added

Source: Bloomberg 

Is Circle behind the record debut?

Responding to Balchunas, another ETF expert, Nate Geraci, speculated

But Ben Johnson, head of client solutions at Morningstar, clarified that the product was funded by other ProShares funds for easier cash management purposes. 

So, why GENIUS Act-inspired? The U.S stablecoin law has several instruments that can be used as reserve assets for issued stablecoin tokens. Some of the permitted reserves include cash and cash equivalents, short-dated U.S. Treasury bills, and money market funds focused on cash management. 

This makes it easier to redeem and to cater to rising demand if users cash out en masse from stablecoins into fiat without triggering a bank run or risking broader financial markets. 

And that’s where the ProShares ETF falls: an MMF focused on stablecoin reserves, likely in the hope that issuers may opt for it for easier cash management, too. It’s unclear whether it will attract these potential issuers. 

Why the SEC’s 2% ‘haircut’ is good for stablecoins

Meanwhile, the stablecoin sector got another win after a recent SEC guideline. The regulator said payment stablecoin will now have 2% haircut, similar to money market funds.

In the past, stablecoins had a 100% ‘haircut’, meaning holding them had no capital benefit. If you had $100 million, it would be seen as $0 for capital purposes. Now, it can be valued at $98 million. 

The change means stablecoin holders can have more trading inventory, loan capacity, and overall financial activity. 

For his part, Jeremy Allaire, CEO of Circle, hailed the move as positive for stablecoin adoption. 


Final Summary 

  • ProShares’ GENIUS Act-inspired ETF set a new record, hitting $17 billion in day-one trading volume. 
  • Circle CEO hailed the SEC’s 2% haircut for stablecoin as a likely catalyst for USDC adoption. 
Next: Bitcoin prices stall – Why BTC’s recovery isn’t confirmed yet

Source: https://ambcrypto.com/proshares-stablecoin-ready-etf-posts-insane-17b-trading-debut/

Market Opportunity
Union Logo
Union Price(U)
$0.000879
$0.000879$0.000879
-1.56%
USD
Union (U) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

And the Big Day Has Arrived: The Anticipated News for XRP and Dogecoin Tomorrow

And the Big Day Has Arrived: The Anticipated News for XRP and Dogecoin Tomorrow

The first-ever ETFs for XRP and Dogecoin are expected to launch in the US tomorrow. Here's what you need to know. Continue Reading: And the Big Day Has Arrived: The Anticipated News for XRP and Dogecoin Tomorrow
Share
Coinstats2025/09/18 04:33
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Rising Altcoin Inflows Signal Potential Market Sell-Off: CryptoQuant

Rising Altcoin Inflows Signal Potential Market Sell-Off: CryptoQuant

        Highlights:  Inflows of altcoins in exchanges have surged by 22% in early 2026. An increase in deposits indicates a growing sell-side pressure. The 
Share
Coinstats2026/02/22 02:03